You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
Boehringer Ingelheim
Baxter
McKinsey

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,252,010

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,252,010 protect, and when does it expire?

Patent 10,252,010 protects XHANCE and is included in one NDA.

This patent has thirty-one patent family members in sixteen countries.

Summary for Patent: 10,252,010
Title:Nasal delivery devices
Abstract: A nasal delivery device for and a method of delivering substance to a nasal airway of a subject, the nasal delivery device including: a mouthpiece (519) through which the subject in use exhales to cause closure of the oropharyngeal velum of the subject; a nosepiece (517) for fitting to a nostril of a subject, the nosepiece including a nozzle (549) through which substance is in use delivered to the nasal airway; and a manually-actuatable substance supply unit (520) for delivering substance through the nozzle of the nosepiece.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Sheldrake; Colin David (Wiltshire, GB)
Assignee: OptiNose AS (Oslo, NO)
Application Number:14/721,097
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 10,252,010

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,252,010

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0719299.0Oct 3, 2007
United Kingdom0806808.2Apr 15, 2008

International Family Members for US Patent 10,252,010

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008306635   Start Trial
Brazil PI0817502   Start Trial
Canada 2701409   Start Trial
China 101918061   Start Trial
Denmark 2653183   Start Trial
European Patent Office 2197525   Start Trial
European Patent Office 2653183   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Baxter
Express Scripts
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.